Table 1 Baseline Characteristics of the Subjects
From: Rivastigmine improves dual-task gait velocity in patients with Alzheimer’s disease
Age (mean, SD) | 79.03 (6.89) | ||
Sex (female; n, %) | 13 (61.9%) | ||
Mini-Mental State Examination (mean, SD) | 19.62 (4.71) | ||
Geriatric Depression Scale (mean, SD) | 2.76 (1.09) | ||
Functional Assessment Staging (mean, SD) | 4.24 (0.83) | ||
Alzheimer’s Disease Cooperative Study Activities of Daily Living (mean, SD) | 63.14 (8.6) | ||
Single-task gait trials | velocity (m/min) | stride length (cm) | cadence (steps/min) |
Normal gait (mean, SD) | 59.21 (12.21) | 50.11 (7.52) | 117.69 (12.26) |
Fast gait (mean, SD) | 70.33 (16.06) | 54.64 (8.58) | 127.69 (13.37) |
Dual-task gait trials | |||
Counting backward by 7 | 40.59 (13.59) | 46 (9.29) | 95.38 (23.88) |
Naming animals | 37.06 (15.57) | 46.25 (9.24) | 80.46 (27.15) |